ENTX vs. ENGN, AMRN, TKNO, CAPR, REPL, CGC, ALEC, MREO, UPXI, and CADL
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include enGene (ENGN), Amarin (AMRN), Alpha Teknova (TKNO), Capricor Therapeutics (CAPR), Replimune Group (REPL), Canopy Growth (CGC), Alector (ALEC), Mereo BioPharma Group (MREO), Upexi (UPXI), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.
Entera Bio vs. Its Competitors
enGene (NASDAQ:ENGN) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.
In the previous week, enGene had 15 more articles in the media than Entera Bio. MarketBeat recorded 16 mentions for enGene and 1 mentions for Entera Bio. enGene's average media sentiment score of 0.43 beat Entera Bio's score of 0.00 indicating that enGene is being referred to more favorably in the media.
enGene has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. enGene's return on equity of -39.86% beat Entera Bio's return on equity.
enGene has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500.
64.2% of enGene shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 10.4% of enGene shares are owned by company insiders. Comparatively, 10.4% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Entera Bio has higher revenue and earnings than enGene. Entera Bio is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.
enGene currently has a consensus target price of $19.50, suggesting a potential upside of 151.61%. Entera Bio has a consensus target price of $10.00, suggesting a potential upside of 426.32%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than enGene.
Summary
enGene beats Entera Bio on 10 of the 15 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
This page (NASDAQ:ENTX) was last updated on 10/4/2025 by MarketBeat.com Staff
